Diagnostic Substances Industry

Below are the top small-cap diagnostic substances stocks on the NYSE and the NASDAQ in terms of revenue estimate for the current year. Neogen (NASDAQ: NEOG) is likely to post revenue of $235.22 million in the year ending May, 2014. Neogen's PEG ratio is 2.85. Analysts expect Meridian Bioscience (...

Below are the top small-cap diagnostic substances stocks on the NYSE and the NASDAQ in terms of operating margin. The trailing-twelve-month operating margin at SurModics (NASDAQ: SRDX) is 32.12%. SurModics had $28.43 million in total cash for the latest quarter. The trailing-twelve-month...

Below are the top small-cap diagnostic substances stocks on the NYSE and the NASDAQ in terms of PEG ratio. SurModics (NASDAQ: SRDX) has a PEG ratio of 1.70. SurModics's trailing-twelve-month revenue is $55.68 million. Trinity Biotech plc (NASDAQ: TRIB) has a PEG ratio of 1.80. Trinity Biotech had...

Below are the small-cap diagnostic substances stocks on the NYSE and the NASDAQ in terms of revenue. The trailing-twelve-month revenue at Abaxis (NASDAQ: ABAX) is $187.18 million. Abaxis's ROE for the same period is 16.18%. The trailing-twelve-month revenue at Meridian Bioscience (NASDAQ: VIVO)...

Below are the top diagnostic substances stocks on the NASDAQ in terms of PEG ratio. Trinity Biotech plc (NASDAQ: TRIB) has a PEG ratio of 1.55. Trinity Biotech n's trailing-twelve-month revenue is $82.97 million. SurModics (NASDAQ: SRDX) has a PEG ratio of 1.69. SurModics had $28.43 million in...

Below are the top diagnostic substances stocks on the NASDAQ in terms of profit margin. The trailing-twelve-month profit margin at Trinity Biotech plc (NASDAQ: TRIB) is 20.40%. Trinity Biotech's revenue for the same period is $82.97 million. The trailing-twelve-month profit margin at Meridian...

Below are the top small-cap diagnostic substances stocks on the NYSE and the NASDAQ in terms of operating margin. The trailing-twelve-month operating margin at Meridian Bioscience (NASDAQ: VIVO) is 30.48%. Meridian Bioscience's revenue for the same period is $184.04 million. The trailing-twelve-...

Below are the top small-cap diagnostic substances stocks on the NYSE and the NASDAQ in terms of PEG ratio. Trinity Biotech plc (NASDAQ: TRIB) has a PEG ratio of 1.43. Trinity Biotech's trailing-twelve-month operating margin is 19.75%. SurModics (NASDAQ: SRDX) has a PEG ratio of 1.47. SurModics's...

Below are the top diagnostic substances stocks on the NASDAQ in terms of cash. AMAG Pharmaceuticals (NASDAQ: AMAG) had $217.07 million in total cash and no debt for the latest quarter. IDEXX Laboratories (NASDAQ: IDXX) had $228.36 million in total cash for the latest quarter. However, IDEXX had $...

Below are the top small-cap diagnostic substances stocks on the NYSE and the NASDAQ in terms of PEG ratio. Trinity Biotech plc (NASDAQ: TRIB) has a PEG ratio of 1.29. Trinity Biotech's trailing-twelve-month operating margin is 20.91%. Meridian Bioscience (NASDAQ: VIVO) has a PEG ratio of 1.60....

Below are the top small-cap diagnostic substances stocks on the NYSE and the NASDAQ in terms of operating margin. The trailing-twelve-month operating margin at SurModics (NASDAQ: SRDX) is 33.41%. SurModics' ROE for the same period is 10.12%. The trailing-twelve-month operating margin at Meridian...

Below are the top diagnostic substances stocks on the NASDAQ in terms of revenue. The trailing-twelve-month revenue at IDEXX Laboratories (NASDAQ: IDXX) is $1.29 billion. IDEXX had $223.99 million in total cash for the latest quarter. The trailing-twelve-month revenue at Meridian Bioscience (...

Below are the top small-cap diagnostic substances stocks on the NYSE and the NASDAQ in terms of earnings estimate for the next quarter. Abaxis (NASDAQ: ABAX) is estimated to post earnings of $0.24 per share in the June quarter. Abaxis' trailing-twelve-month revenue is $178.79 million. Meridian...

Below are the top diagnostic substances stocks on the NASDAQ in terms of revenue estimate for the current year. Analysts expect IDEXX Laboratories (NASDAQ: IDXX) to post revenue of $1.30 billion for the year ending December, 2012. IDEXX had $221.44 million in total cash for the latest quarter....

Below are the top diagnostic substances stocks on the NASDAQ in terms of profit margin. The trailing-twelve-month profit margin at Trinity Biotech plc (NASDAQ: TRIB) is 20.71%. Trinity Biotech's revenue for the same period is $81.70 million. The trailing-twelve-month profit margin at Meridian...